By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Exelixis, Inc. 

210 East Grand Avenue

South San Francisco  California  94083-0511  U.S.A.
Phone: 650-837-7000 Fax: 650-837-8300

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo.

By investing in robust discovery and preclinical development infrastructure, the company has been able to bring very high quality compounds into the clinic in rapid fashion. Just four years after filing its first investigational new drug application (IND) to begin clinical trials of a proprietary compound, Exelixis has 14 compounds in clinical development and is positioned to build a leading franchise in cancer therapeutics.

A fundamental philosophy at Exelixis is the belief that advancing the treatment of cancer necessitates increased understanding of the disease itself. A key component of the company’s strategy is to gain insight into the complex molecular mechanisms that drive the growth, survival, and resistance of cancer cells, and utilize this knowledge to simplify, streamline, and inform the entire drug development process. This approach allows Exelixis to be both innovative and strategic while moving quickly in the right direction.

Recognizing that diverse molecular pathways impact the development, progression, spread, and survival of different cancer types, Exelixis is building a pipeline of compounds with unique target profiles. This approach allows the development of individual drug candidates for those cancer indications and patient populations where the pharmacology of the compound addresses the biology of the disease.

Exelixis’ ability to take this approach is a result of the company’s extensive expertise in pathway biology, and is supported by an integrated approach to discovery, translational medicine, and clinical development. Everyone at Exelixis believes that extensive discovery research isn’t just good science – it is also critical to good medicine. By understanding target biology and compound activity early on, Exelixis researchers seek to identify those patients most likely to benefit from a given drug candidate, and pursue a clearly defined path through the clinic and toward the market.

To support its robust and growing product pipeline, Exelixis is establishing a seamlessly integrated R&D organization with the critical mass to leverage data effectively and the flexibility to incorporate new insights into our strategies. The ability to make rational and data-driven decisions at each point along the drug development continuum strengthens the entire process. Extensive target characterization enhances the company’s ability to select indications and patient populations in which its drug candidates are most likely to provide benefit, and its experiences in the clinic help to identify additional areas of unmet medical need on which future discovery and development efforts can be focused.

Key Statistics

Ownership: Public

Web Site: Exelixis
Employees: 450
Symbol: EXEL



Bristol-Myers Squibb Pharmaceutical Research Institute  Mechanism of Action, Agreement signed September 1999, expanded June 2000

Pharmacia Corporation  Alzheimer's disease and metabolic syndrome, Agreement signed February 1999, expanded October 1999

PanVera LLC 

Merck & Co.  High-throughput screening

Company News
Ipsen (IPN.PA)’s Partner Exelixis (EXEL) Announced Results From Randomized Phase 2 Trial CABOSUN That Demonstrate That Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 5/24/2016 10:59:01 AM
Exelixis (EXEL)' Cabozantinib Met Primary Endpoint in Phase II Renal Cell Carcinoma Study 5/23/2016 7:23:41 AM
Exelixis (EXEL) To Present At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference On May 10 5/6/2016 9:04:38 AM
Exelixis (EXEL) Announces First Quarter 2016 Financial Results And Provides Corporate Update 5/5/2016 9:56:34 AM
Exelixis (EXEL) To Release First Quarter 2016 Financial Results On Wednesday, May 4, 2016 4/27/2016 10:58:43 AM
Ipsen (IPN.PA) Is Pleased To Announce That Its Partner Exelixis (EXEL) Obtained FDA Approval Of CABOMETYX (Cabozantinib) Tablets For Patients With Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy 4/26/2016 12:42:28 PM
Exelixis (EXEL)-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting 4/20/2016 10:40:29 AM
Better Buy: Exelixis (EXEL) Or Bristol-Myers Squibb (BMY) 3/16/2016 8:11:44 AM
Exelixis (EXEL) To Present At Two Investor Conferences In March 3/4/2016 10:48:42 AM
Exelixis (EXEL) Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update 3/1/2016 11:49:42 AM